{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:49:30Z","timestamp":1767142170816,"version":"build-2238731810"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,4,28]],"date-time":"2016-04-28T00:00:00Z","timestamp":1461801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s12185-016-2005-3","type":"journal-article","created":{"date-parts":[[2016,4,28]],"date-time":"2016-04-28T13:04:49Z","timestamp":1461848689000},"page":"208-215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A cohort study of the usefulness of primary prophylaxis in patients with severe haemophilia A"],"prefix":"10.1007","volume":"104","author":[{"given":"Chiai","family":"Nagae","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuki","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Ashikaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mieko","family":"Akita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Kitsukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimie","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Taki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,28]]},"reference":[{"issue":"Suppl 1","key":"2005_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2516.9.s1.17.x","volume":"9","author":"E Berntorp","year":"2003","unstructured":"Berntorp E, Astermark J, Bj\u00f6rkman S, Blanchette VS, Fischer K, Giangrande PL, et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia. 2003;9(Suppl 1):1\u20134.","journal-title":"Haemophilia"},{"key":"2005_CR2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2516.2006.01409.x","volume":"13","author":"S Ota","year":"2007","unstructured":"Ota S, Mclimont M, Carcao MD, Blanchette VS, Graham N, Paradis E, et al. Definitions for haemophilia prophylaxis and its outcomes: the Canadian consensus study. Haemophilia. 2007;13:12\u201320.","journal-title":"Haemophilia"},{"key":"2005_CR3","doi-asserted-by":"crossref","unstructured":"Nilsson IM, Blomback M, Ahlberg A. Our experience in Sweden with prophylaxis on haemophilia. In: Proceedings of the 5th congress of the world federation of haemiphilia, Montreal 1968; Bibl Haematol, vol 34, p. 111\u201324, New York: Karger; 1970.","DOI":"10.1159\/000384903"},{"key":"2005_CR4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1651-2227.1976.tb16525.x","volume":"65","author":"IM Nilsson","year":"1976","unstructured":"Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand. 1976;65:129\u201335.","journal-title":"Acta Paediatr Scand."},{"key":"2005_CR5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2796.1997.130135000.x","volume":"241","author":"T Lofqvist","year":"1997","unstructured":"Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients\u2014a long term follow up. J Intern Med. 1997;241:395\u2013400.","journal-title":"J Intern Med"},{"key":"2005_CR6","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/jama.1994.03520150019005","volume":"272","author":"AA Skolnick","year":"1994","unstructured":"Skolnick AA. Hemophilia foundation recommends prophylactic use of clotting factors. JAMA. 1994;272:1153\u20134.","journal-title":"JAMA"},{"key":"2005_CR7","first-page":"691","volume":"73","author":"E Berntorp","year":"1995","unstructured":"Berntorp E, Boulyjenkov V, Brettler D, Chandy M, Jones P, Lee C, et al. Modern treatment of haemophilia. Bull World Health Organ. 1995;73:691\u2013701.","journal-title":"Bull World Health Organ"},{"issue":"3, Suppl 2","key":"2005_CR8","first-page":"3","volume":"30","author":"MS Gilbert","year":"1993","unstructured":"Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semi Hematol. 1993;30(3, Suppl 2):3\u20136.","journal-title":"Semi Hematol"},{"key":"2005_CR9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00003086-198006000-00018","volume":"149","author":"H Pettersson","year":"1980","unstructured":"Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res. 1980;149:153\u20139.","journal-title":"Clin Orthop Relat Res"},{"key":"2005_CR10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2516.2005.01049.x","volume":"11","author":"B Lundin","year":"2005","unstructured":"Lundin B, Babyn P, Doria AS, Kilcoyne R, Ljung R, Miller S, et al. Compatible scales for progressive and additive MRI assessments of haemophilic arthropathy. Haemophilia. 2005;11:109\u201315.","journal-title":"Haemophilia"},{"key":"2005_CR11","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2491\/jjsth.14.350","volume":"14","author":"S Higasa","year":"2003","unstructured":"Higasa S, Arai M, Shima M, Shirahata A, Takada N, Takamatsu J, et al. Home infusion therapy guidelines for hemophilia. J Thromb Haemost. 2003;14:350\u20138 (Japanese).","journal-title":"J Thromb Haemost."},{"key":"2005_CR12","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1538-7836.2011.04228.x","volume":"9","author":"MX Hang","year":"2011","unstructured":"Hang MX, Blanchette VS, Pullenayegum E, Mclimont M, Feldman BM. Age at first joint bleed and bleeding severity in boys with severe hemophilia A: Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost. 2011;9:1067\u20139.","journal-title":"J Thromb Haemost"},{"key":"2005_CR13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","volume":"357","author":"MJ Manco-Johnson","year":"2007","unstructured":"Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535\u201344.","journal-title":"N Engl J Med"},{"key":"2005_CR14","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/blood-2006-11-056291","volume":"109","author":"SC Gouw","year":"2007","unstructured":"Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007;109:4648\u201354.","journal-title":"Blood"},{"key":"2005_CR15","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2516.2009.02122.x","volume":"16","author":"K Kurnik","year":"2010","unstructured":"Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia. 2010;16:256\u201362.","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"2005_CR16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1538-7836.2009.03437.x","volume":"7","author":"HM Berg van den","year":"2009","unstructured":"van den Berg HM, Chalmers EA. Clinical prediction models for inhibitor development in severe hemophilia A. J Thromb Haemost. 2009;7(Suppl 1):98\u2013102.","journal-title":"J Thromb Haemost"},{"key":"2005_CR17","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","volume":"121","author":"SC Gouw","year":"2013","unstructured":"Gouw SC, van den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121:4046\u201355.","journal-title":"Blood"},{"key":"2005_CR18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/hae.12566","volume":"21","author":"SM Hashemi","year":"2015","unstructured":"Hashemi SM, Fischer K, Moons KG, van den Berg HM. Improved prediction of inhibitor development in previously untreated patients with severe haemophilia A. Haemophilia. 2015;21:227\u201333.","journal-title":"Haemophilia"},{"key":"2005_CR19","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/0140-6736(92)91324-2","volume":"339","author":"R Ljung","year":"1992","unstructured":"Ljung R, Petrini P, Lindgren AC, Tengborn L, Nilsson IM. Factor VIII and factor IX inhibitors in haemophiliacs. Lancet. 1992;339:1550\u20131.","journal-title":"Lancet"},{"key":"2005_CR20","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/0140-6736(93)91593-B","volume":"342","author":"J Addiego","year":"1993","unstructured":"Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet. 1993;342:462\u20134.","journal-title":"Lancet"},{"key":"2005_CR21","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJM199012273232604","volume":"323","author":"RS Schwartz","year":"1990","unstructured":"Schwartz RS, Abildgaard CF, Aledort LM, Arkin S, Bloom AL, Brackmann HH, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. Recombinant Factor VIII Study Group. N Engl J Med. 1990;323:1800\u20135.","journal-title":"N Engl J Med"},{"key":"2005_CR22","first-page":"2428","volume":"83","author":"GL Bray","year":"1994","unstructured":"Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, et al. A multicenter study of recombineant factor VIII (recombineate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood. 1994;83:2428\u201335.","journal-title":"Blood."},{"key":"2005_CR23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1046\/j.1365-2516.2003.00708.x","volume":"9","author":"JM Lusher","year":"2003","unstructured":"Lusher JM, Lee CA, Kessler CM, Bedrosian CL. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. ReFacto Phase 3 Study Group. Haemophilia. 2003;9:38\u201349.","journal-title":"Haemophilia"},{"key":"2005_CR24","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1111\/hae.12121","volume":"19","author":"A Farrugia","year":"2013","unstructured":"Farrugia A, Cassar J, Kimber MC, Bansal M, Fischer K, Auserswald G, et al. Treatment for life for severe haemophilia A: a cost-utility model for prophylaxis versus on-demand treatment. Haemophilia. 2013;19:e228\u201338.","journal-title":"Haemophilia"},{"key":"2005_CR25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3111\/13696998.2015.1016228","volume":"18","author":"ZY Zhou","year":"2015","unstructured":"Zhou ZY, Koerper MA, Johnson KA, Riske B, Baker JR, Ullman M, et al. Burden of illness: direct and indirect costs among persons with hemophilia A in the United States. J Med Econ. 2015;18:457\u201365.","journal-title":"J Med Econ."},{"key":"2005_CR26","unstructured":"Taki M, Yoshioka A, Shirahata A, Mimaya J, Ueda K, Hanada R, et al. The prospective study on the prophylaxis of coagulation factor concentrates for infants with severe haemophilia. In: Proceedings of the 46th annual meeting of the Japanese Society of Pediatric Hematology; 2004 Nov 22\u201323; Kyoto, JPN. Tokyo: The Japanese Society of Pediatric Hematology; 2004, p. 273. (Japanese)."},{"key":"2005_CR27","unstructured":"Japanese Foundation for AIDS Prevention. Official Report of National Surveillance on Coagulation Disorders in Japan 2013. Published by Japanese Foundation for AIDS Prevention, Tokyo."}],"updated-by":[{"DOI":"10.1007\/s12185-016-2055-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T00:00:00Z","timestamp":1467244800000}}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2005-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-016-2005-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2005-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T21:47:34Z","timestamp":1655588854000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-016-2005-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,28]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["2005"],"URL":"https:\/\/doi.org\/10.1007\/s12185-016-2005-3","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,28]]}}}